SomaLogic Launching Validation and Prospective Trials for Protein Biomarker Lung Cancer Diagnostic
December 10, 2010
SomaLogic Launching Validation and Prospective Trials for Protein Biomarker Lung Cancer Diagnostic
The test is intended both for early screening purposes and the differential diagnoses of lung nodules detected during CT scans and x-rays. SomaLogic has partnered with Quest Diagnostics to commercialize the test, with a lab-developed version slated for launch next year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
April 22, 2011 / ProteoMonitor - Somalogic Launches Validation Studies of Protein Biomarkers for Pancreatic Cancer and Mesothelioma
October 15, 2010 / ProteoMonitor - NYU, Somalogic Present Data on Protein Biomarker Test for Mesothelioma
April 8, 2011 / ProteoMonitor - With Novartis Deal, Release of New Discovery Panel, Somalogic Targets Proteomics Services Market
October 21, 2011 / ProteoMonitor - Lung Cancer Study Highlights Current Limitations of MALDI Mass Spec
July 22, 2011 / ProteoMonitor